Home › Agent Hub › Agent Tools › Part D coverage by drug › Movantik

Agent Tools

Movantik Part D coverage 2027

Movantik is a brand of naloxegol. What agents check before quoting it: how many 2027 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.

Coverage at a glance

In 2027, 5,307 of 5,492 Medicare Part D and Medicare Advantage drug plans (96.6%) list Movantik on their formulary, across 264 of 286 formularies. The most common placement is tier 3 (4,483 plans, 84.5% of those covering it). 188 of the covering plans require prior authorization (3.5%), 0 step therapy and 5,157 a quantity limit.

What a 30-day fill costs

545 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $42, 74 of them $0; 4,762 charge coinsurance instead — median 22% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,400 in 2027, covered drugs cost $0 for the rest of the year.

What changed since 2026

2026: 5,263 of 5,496 plans covered it (95.8%); 2027: 5,307 of 5,492 (96.6%).

Of 4,367 plans offered in both years, 35 added it to the formulary and 3 dropped it.

Among plans covering it both years, 50 moved it to a higher tier and 234 to a lower one; 22 added prior authorization and 5 removed it.

Tier placement

By plan type

By carrier

By state

Medicare usage

Medicare Part D paid for 407,938 30-day fills of Movantik in 2024 for about 80,660 enrollees, at an average total cost of $369.14 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).

Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 10/08/2026). CMS formulary data.